ES2680418R1 - Uso de un compuesto en la fabricación de un medicamento útil para el tratamiento por activación de la expresión de la proteína CIRP de una enfermedad y composición - Google Patents

Uso de un compuesto en la fabricación de un medicamento útil para el tratamiento por activación de la expresión de la proteína CIRP de una enfermedad y composición

Info

Publication number
ES2680418R1
ES2680418R1 ES201730249A ES201730249A ES2680418R1 ES 2680418 R1 ES2680418 R1 ES 2680418R1 ES 201730249 A ES201730249 A ES 201730249A ES 201730249 A ES201730249 A ES 201730249A ES 2680418 R1 ES2680418 R1 ES 2680418R1
Authority
ES
Spain
Prior art keywords
activation
disease
expression
manufacture
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES201730249A
Other languages
English (en)
Other versions
ES2680418A2 (es
ES2680418B1 (es
Inventor
Loidl César Fabián
Funes Manuel Eduardo Rey
Ramirez Alfredo Martinez
Roldán Ignacio Larráyoz
Cristóbal Rafael Peláez
Pascual Teresa Beatriz De
González Ana María Ramos
Boué Claire Coderch
Rodríguez Jose María Zapico
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fundacion Universitaria San Pablo CEU
Fundacion Rioja Salud
Original Assignee
Fundacion Universitaria San Pablo CEU
Fundacion Rioja Salud
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacion Universitaria San Pablo CEU, Fundacion Rioja Salud filed Critical Fundacion Universitaria San Pablo CEU
Priority to ES201730249A priority Critical patent/ES2680418B1/es
Publication of ES2680418A2 publication Critical patent/ES2680418A2/es
Publication of ES2680418R1 publication Critical patent/ES2680418R1/es
Application granted granted Critical
Publication of ES2680418B1 publication Critical patent/ES2680418B1/es
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES201730249A 2017-02-24 2017-02-24 Uso de un compuesto en la fabricación de un medicamento útil para el tratamiento por activación de la expresión de la proteína CIRP de una enfermedad y composición Expired - Fee Related ES2680418B1 (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES201730249A ES2680418B1 (es) 2017-02-24 2017-02-24 Uso de un compuesto en la fabricación de un medicamento útil para el tratamiento por activación de la expresión de la proteína CIRP de una enfermedad y composición

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201730249A ES2680418B1 (es) 2017-02-24 2017-02-24 Uso de un compuesto en la fabricación de un medicamento útil para el tratamiento por activación de la expresión de la proteína CIRP de una enfermedad y composición

Publications (3)

Publication Number Publication Date
ES2680418A2 ES2680418A2 (es) 2018-09-06
ES2680418R1 true ES2680418R1 (es) 2019-01-17
ES2680418B1 ES2680418B1 (es) 2019-10-25

Family

ID=63372685

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201730249A Expired - Fee Related ES2680418B1 (es) 2017-02-24 2017-02-24 Uso de un compuesto en la fabricación de un medicamento útil para el tratamiento por activación de la expresión de la proteína CIRP de una enfermedad y composición

Country Status (1)

Country Link
ES (1) ES2680418B1 (es)

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BOOTH R G et al. QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP OF TRIAZINE-ANTIFOLATE INHIBITION OF LEISHMANIA DIHYDROFOLATE REDUCTASE AND CELL GROWTH. Journal of Medicinal Chemistry 1987. , 30/11/1986, Vol. 30, Nº 7, Páginas 1218-1224 ISSN 0022-2623, Tabla I, compuesto 10 *
DEMKOWICZ, Sebastian et al . NEW CLICKED FULL AGONISTS OF THE ESTROGEN RECETOR BETA. The Royal Society of Chemistry, 2013, Vol. 3, Páginas 3697-3706 (DOI: 10.1039/c3ra00122a) Figura 2 *
Koehler M G et al. A MOLECULAR SHAPE ANALYSIS AND QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP INVESTIGATION OF SOME TRIAZINE-ANTIFOLATE INHIBITORS OF LEISHMANIA DIHYDROFOLATE REDUCTASE. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 19881001 Academic Press, US. Valpuesta Josï¿¿ M; Carrascosa Josï¿¿ L, 01/10/1988, Vol. 266, Nº 1, Páginas 152 - 161 ISSN 0003-9861, (DOI: doi:10.1016/0003-9861(88)90245-7) Tabla I, compuesto a7. *
MASLYK, MACIEJ et al . IN SEARCH OF A NEW PROTOTYPE IN CK2 INHITORS DESIGN. ARKIVOC, 2010, Vol. iii, Páginas 54-71 (DOI: http://dx.doi.org/10.3998/ark.5550190.0012.306) Esquema 1, compuestos 8 y 9 *
NOELL C W et al. POTENTIAL PURINE ANTAGONISTS. XXXI. THE PREPARATION OF CERTAIN 9-ALKYL-2-AMINO-6-PURINETHIOLS AND RELATED DERIVATIVES AS ANTITUMOR AGENTS.. Journal of medicinal and pharmaceutical chemistry United States May 1962. , 30/04/1962, Vol. 91, Páginas 558 - 588 ISSN 0095-9065 (Print), (DOI: pubmed:14056392) pagina 563, fórmula X, Tabla V. *
Pagliai Francesca et al. RAPID SYNTHESIS OF TRIAZOLE-MODIFIED RESVERATROL ANALOGUES VIA CLICK CHEMISTRY. Journal of Medicinal Chemistry JAN 26 2006. , 26/01/2006, Vol. 49, Nº 2, Páginas 467-470 ISSN 0022-2623(print) ISSN 1520-4804(electronic), (DOI: doi:10.1021/jm051118z) Figura 1 *

Also Published As

Publication number Publication date
ES2680418A2 (es) 2018-09-06
ES2680418B1 (es) 2019-10-25

Similar Documents

Publication Publication Date Title
CL2020002043A1 (es) Métodos y composiciones para la entrega de proteínas terapeuticas.
NI201700011A (es) 2-(morfolin-4-il)-1,7-naftiridinas.
SV2018005610A (es) Derivados de oxopiridina sustituidos
CL2018002814A1 (es) Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel.
CR20170411A (es) Composiciones farmacéuticas que comprenden n-(3,5-dimetoxifenil)-n-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il-quin oxalin-6-il]etano-1,2-diamina
CL2015003690A1 (es) Uso de pridopidina o una sal de la misma para preparar un medicamento útil en el tratamiento de la enfermedad de huntington.
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
IL268850A (en) Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
PT3481846T (pt) 24-hidroxiesteroides 11-substituídos para utilização no tratamento de afeções relacionadas com nmda
CL2015003117A1 (es) Modificaciones en la estructura cristalina
BR112016020199A2 (pt) Composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
BR112015031475A2 (pt) composto, composição farmacêutica, método para tratamento de uma doença ou condição, kit, e, uso de composto.
BR112014010177A2 (pt) composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
UY35293A (es) Isotiazoles sustituidos con amino
MX2018012285A (es) Metodos de tratamiento para enfermedades colestasicas y fibroticas.
MX2016014859A (es) Composiciones farmaceuticas que comprenden danirixina para tratar enfermedades infecciosas.
CR20160016A (es) Pirazolpiridinas sustituidas
PL3732294T3 (pl) Tymohydrochinon do stosowania w leczeniu hiperglikemii
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
CL2019003288A1 (es) Una combinación farmacéutica para el tratamiento de un cáncer.
MX2021002444A (es) Compuestos y metodos para el tratamiento de infecciones fungicas.
CL2016001054A1 (es) Compuestos para el tratamiento de diabetes y complicaciones de enfermedades derivadas de la misma

Legal Events

Date Code Title Description
BA2A Patent application published

Ref document number: 2680418

Country of ref document: ES

Kind code of ref document: A2

Effective date: 20180906

EC2A Search report published

Ref document number: 2680418

Country of ref document: ES

Kind code of ref document: R1

Effective date: 20190110

FG2A Definitive protection

Ref document number: 2680418

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20191025

FD2A Announcement of lapse in spain

Effective date: 20211004